The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 27, 2025
Filed:
Dec. 11, 2023
Applicant:
United Therapeutics Corporation, Silver Spring, MD (US);
Inventors:
Roger Jeffs, Chapel Hill, NC (US);
Thomas Petersen, Durham, NC (US);
Roger M. Ilagan, Burlington, NC (US);
Michael Wade, Chapel Hill, NC (US);
Assignee:
United Therapeutics Corporation, Silver Spring, MD (US);
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/44 (2015.01); A61K 31/5585 (2006.01); A61K 35/02 (2015.01); A61K 35/28 (2015.01); A61K 45/06 (2006.01); C12N 5/071 (2010.01);
U.S. Cl.
CPC ...
A61K 35/44 (2013.01); A61K 31/5585 (2013.01); A61K 35/02 (2013.01); A61K 35/28 (2013.01); A61K 45/06 (2013.01); C12N 5/0692 (2013.01); C12N 2501/999 (2013.01); F04C 2270/041 (2013.01);
Abstract
The current application is directed to a method for treating pulmonary arterial hypertension (PAH), comprising: providing isolated endothelial progenitor cells (EPCs); treating the EPCs with prostacyclin, wherein the treated EPCs exhibit a hyperproliferative phenotype with enhanced angiogenic property; and administering a composition comprising the treated EPCs into a subject suffering from PAH.